BSKB Represents Petitioner in IPR Invalidation of Claims of BioPharma Patents
March 2015 – BSKB team (Gerald M. Murphy Jr., MaryAnne Armstrong, Ph.D., Eugene T. Perez and Lynde F. Herzbach) represented the petitioner in what appear to be the first final decisions in an inter partes review (IPR) in the biopharmaceutical field. In these decisions, the Patent Trial and Appeal Board (PTAB) held that the challenged claims of two patents owned by Genzyme and one patent owned by Duke University were invalid over prior art. The patents were directed to a method of treating Pompe disease by enzyme replacement therapy. For copies of the decisions, please see IPR2013-00537, IPR2013-00534 and IPR2013-00535.